EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 370 filers reported holding EXELIXIS INC in Q3 2020. The put-call ratio across all filers is 2.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $220,000 | -1.8% | 9,251 | -26.8% | 0.07% | -22.4% |
| Q3 2019 | $224,000 | -16.4% | 12,646 | +0.8% | 0.08% | -19.8% |
| Q2 2019 | $268,000 | -16.8% | 12,546 | -7.4% | 0.11% | -13.1% |
| Q1 2019 | $322,000 | +37.6% | 13,546 | +14.1% | 0.12% | +15.1% |
| Q4 2018 | $234,000 | +11.4% | 11,871 | 0.0% | 0.11% | +27.7% |
| Q3 2018 | $210,000 | -17.6% | 11,871 | 0.0% | 0.08% | -18.6% |
| Q2 2018 | $255,000 | -3.0% | 11,871 | 0.0% | 0.10% | +21.4% |
| Q1 2018 | $263,000 | -27.1% | 11,871 | 0.0% | 0.08% | -28.8% |
| Q4 2017 | $361,000 | +25.3% | 11,871 | 0.0% | 0.12% | +38.8% |
| Q3 2017 | $288,000 | -1.4% | 11,871 | 0.0% | 0.08% | -2.3% |
| Q2 2017 | $292,000 | +13.6% | 11,871 | -0.1% | 0.09% | +16.0% |
| Q1 2017 | $257,000 | +45.2% | 11,880 | 0.0% | 0.08% | +50.0% |
| Q4 2016 | $177,000 | – | 11,880 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,966,038 | $282,918,000 | 60.81% |
| NEXTHERA CAPITAL LP | 1,735,030 | $30,745,000 | 5.89% |
| GREAT POINT PARTNERS LLC | 2,075,000 | $36,769,000 | 5.73% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 704,534 | $9,574,000 | 4.55% |
| Matrix Capital Management Company, LP | 10,000,000 | $177,200,000 | 4.38% |
| Consonance Capital Management LP | 3,879,050 | $68,737,000 | 3.70% |
| Rhenman & Partners Asset Management AB | 1,261,414 | $22,352,000 | 2.24% |
| BB BIOTECH AG | 2,785,000 | $49,350,000 | 1.31% |
| CAPITAL MANAGEMENT CORP /VA | 285,575 | $5,060,000 | 1.29% |
| TEALWOOD ASSET MANAGEMENT INC | 155,376 | $2,753,000 | 1.03% |